Get notified when ABCL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Strategic Pivot to Internal Pipeline (new) — The company added a risk factor describing its shift from a partnership-focused model to developing its own internal pipeline, which may reduce near-term revenue and increase cash costs.
- New Financing Covenants (new) — December 2025 financing secured against the office building imposes restrictive covenants, including change-of-control provisions and restrictions on property transfer.
AbCellera revenue falls 76.3% to $4.0M; net loss narrows to -$55.4M on new Jazz and Vertex deals
Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read
Key Changes
-
high
Subsequent event: In July 2026, the Company entered into a collaboration agreement with Vertex Pharmaceuticals Inc. to develop multispecific T-cell engagers. The Company received $28.0 million upfront upon the execution of the agreemen…
Notes: Subsequent Events verify on EDGAR → -
high
Total revenue fell 76.3% to $4.0M, driven by lower licensing income; operating loss widened to $62.8M.
MD&A: Revenue verify on EDGAR → -
high
New collaborations with Jazz ($56M upfront) and Vertex ($28M upfront) added $84M in cash and expanded the T-cell engager pipeline.
MD&A: New collaborations verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.
Partner
Trade ABCL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify